Story

AbCellera Shares Surge 22% on Positive Phase 2 Menopause Drug Trial Data

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20261 min read
AbCellera Shares Surge 22% on Positive Phase 2 Menopause Drug Trial Data
Text size
Background

AbCellera Biologics Inc. (NASDAQ:ABCL) shares surged by as much as 22% on Monday after the company reported positive top-line results from a Phase 2 clinical trial for ABCL635, an investigational treatment for moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause.

Trial Meets Primary Endpoints

The company announced that the Phase 2 study successfully met its primary efficacy endpoints. After a single dose, ABCL635 demonstrated a statistically significant reduction in both the frequency and severity of hot flashes at week four compared to a placebo.

According to the results, the treatment led to a significant decrease in symptoms:

  • Frequency: A placebo-adjusted reduction of 5.3 moderate-to-severe vasomotor events per day.
  • Severity: A placebo-adjusted reduction of 1.1 points on a severity scale.

The trial also showed improvements in sleep and in patients' global impression of change, AbCellera reported.

Sample IUX Markets – In-articleAd

Study Details and Safety Profile

The randomized, double-blind, placebo-controlled trial involved 92 postmenopausal women who were experiencing approximately 10 moderate or severe hot flashes daily. Participants received either a single 600 mg subcutaneous dose of ABCL635 or a placebo.

AbCellera stated that ABCL635 was well-tolerated over the four-week treatment period. The company reported no serious or severe adverse events, and no participants discontinued the study due to adverse events. The most common side effects observed in the treatment group were headache, fatigue, and injection site reactions.

Context for Investors

The positive data represents a key milestone for AbCellera, which is developing ABCL635 as a non-hormonal, long-acting, subcutaneous treatment. The drug targets the neurokinin 3 receptor. Following the announcement, the company held a conference call on Monday to discuss the trial results with investors and analysts.

Read next

More on Stocks
Back to latest news

LATEST